Ad pushes behind brands like Gilead Sciences’ hepatitis-C pill Harvoni and Allergan’s IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.
Print has been written off so often as being obsolete and unwieldy that it seems a wonder that it is still with us. So why does Kantar Media data for the first half of 2015 suggest that print remains vital? Rebecca Mayer Knutsen breaks down the numbers—and through the conventional wisdom
A few years ago medical publishers were approaching a cliff and the choices were simple: Evolve the business or fall over the edge. By having learned to survive, some publishers are now ready to thrive
Print’s numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what 2014’s slight uptick means in the context of an evolving media mix
The downward spiral for journals continues. Is anyone surprised? Larry Dobrow on how the fundamental shift to digital continued to affect professional media last year, including the full-year numbers by advertisers and brands
No one expected the numbers to be pretty. And medical/surgical journals’ latest losses weren’t. Larry Dobrow analyzes the numbers for the first half of 2013 by advertisers and brands
Pharma’s turn to specialty drugs hasn’t been good for print. Ad pages in medical/surgical journals fell steeply in 2012, despite the pickup in FDA approvals. Larry Dobrow reports the full-year numbers
Ad spend for medical/surgical journals declined by 16.5%, as patent expiries and regulatory delays stifled 2011’s comeback bid. Marc Iskowitz reports on the numbers for the first half of 2012
Medical/surgical journal advertising grew in 2011, the second consecutive year it’s been in the black. Marc Iskowitz on which categories and brands attracted the most advertising dollars
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix